HIV and Hepatitis Policy Institute

11/10/2025

Delta Failing Their Employees by Restricting Access to PrEP Drugs--Clear Violation of ACA Preventive Services Requirement: https://bit.ly/497ootO

11/06/2025

Cuts to Prevention and Treatment Funding:

As the federal government shutdown proceeds through day 37, SNAP recipients are feeling the shortfall. Federal cuts to HIV funding are having dangerous effects on efforts to educate, prevent and treat. Bartow’s own James Van Fleet played a pivotal role in Allied victory in WWII.

10/30/2025

The HIV and Hepatitis Policy Institute's Carl Schmid testified in support of Zachary Parker, Ward 5 Member, DC State Board of Education's DC Act of 2025 that prohibits & for all PrEP & PEP so that DC residents can access the latest prevention drugs w/o relying on federal mandates:

Testimony by Carl Schmid Executive Director, HIV+Hepatitis Policy Institute in support of PrEP DC Act of 2025 (B26-0159) Committee on Health, Council of the District of Columbia October 30, 2025

10/22/2025

CVS Caremark tells activists Gilead needs to lower the price of its new drug to get on formularies:

CVS Caremark, the largest PBM in the U.S., tells activists Gilead needs to lower the price of its new HIV drug to get on formularies, according to an email obtained by STAT.

10/01/2025

Contrary to federal law and despite our earlier complaint & their assurances, Delta Air Lines is telling its employees they must use generic to prevent rather than newer & long-acting PrEP ’s. Read our letter to Delta: https://bit.ly/46E5MP2

09/29/2025

https://www.route-fifty.com/artificial-intelligence/2025/09/stopping-federal-moratorium-empowers-states-continue-robust-tailored-ai-oversight/408381/

COMMENTARY | The 10-year block on state laws regulating the technology would have created uncertainty, something that would have weakened the insurance market and delayed consumer protections.

09/25/2025

In BenefitsPRO, the HIV and Hepatitis Policy Institute urges Secretary Lori Chavez-DeRemer to stop drug middlemen from profiting by classifying as "non-Essential Health Benefits" to extract billions of dollars of meant for for themselves:

Benefits professionals would be wise to recognize these schemes for what they are — and avoid them.

09/25/2025

CVS Health says ‘no’ to six-month PrEP drug Yeztugo:

Citing cost, CVS Health Corporation, parent of the pharmacy benefit manager (PBM) CVS Caremark, won’t be adding Yeztugo, the twice-yearly injectable HIV prevention (PrEP) medication from drugmaker Gilead Sciences, to its formularies—at least for now.